Tuberculous peritonitis [6]

American Journal of Gastroenterology

Volumn 100, Issue 7, 2005, Pages 1624-1625

  Finlay, Darrell G ^a   Szauter, Karen ^a   Raju, Gottumukkala S ^a   Snyder, Ned ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; ANKYLOSING SPONDYLITIS; ASCITES; CASE REPORT; DYSPNEA; FEVER; HUMAN; LETTER; MALE; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TUBERCULOUS PERITONITIS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; MICROBIOLOGY; PHYSIOLOGY; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASCITES; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PERITONITIS, TUBERCULOUS; RECURRENCE; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22744440630     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.50006_8.x     Document Type: Letter

References (4)

1. Keane J. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-04.
2. Gomez-Reino JJ., Carmona L., Valverde VR., Mola EM., Montera MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis & Rheumatism 2003;48(8):2122-7.
3. Horsburgh C. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:2060-7.
4. Personal Communication: Centocor (Infliximab Manufacturer).